Following the resignation of Aili general manager Mou Yanping as the general manager of the company for personal reasons, recently, another pharmaceutical company announced the resignation of the general manager
.
On the evening of September 14, Jiaying Pharmaceutical issued an announcement that Mr.
Zhurai resigned as general manager of the company for personal reasons
.
Mr.
Churai continued to serve as Chairman of the Board of Directors of the Company after his resignation
.
According to the data, Jiaying Pharmaceutical is a proprietary Chinese medicine company
integrating R&D, production and sales listed in 2007.
According to the first quarter report of 2022, the company achieved operating income of 120 million yuan, down 1.
13% year-on-year; The net profit attributable to the shareholders of the listed company was 2.
5356 million yuan, down 67.
34%
year-on-year.
Since the beginning of this year, the senior management of pharmaceutical companies has changed, and a large number of senior executives such as general managers of pharmaceutical companies have resigned for personal reasons, work adjustments and other reasons, and it has been particularly frequent
since the second half of the year.
For example, on August 23, Jinyao Da Ren Tang announced that the company had received a written resignation from Li Yan on August 22, and Li Yan applied to resign as general manager and director of the company due to job changes, and no longer held any position
in Da Ren Tang after resigning.
On July 29, China Pharmaceutical announced that Wang Hongxin resigned as general manager and director due to work adjustments, and will no longer hold any position in
the company after resigning.
On July 28, Zixin Pharmaceutical issued an announcement that due to the transfer of work, general manager Feng Youshun applied to resign as the general manager of the company, and the nomination committee of the board of directors nominated Meng Xiangjin as the general manager of the
company.
On July 26, Renhe Pharmaceutical announced that Mr.
Zhang Wei applied to the board of directors of the company to resign as director and general manager of the company due to work adjustment, and resigned from the strategic committee and nomination committee of the board of directors
.
.
.
.
.
.
.
Behind the personnel adjustment of pharmaceutical companies, the trend of industry changes can be reflected
.
From the perspective of pharmaceutical companies whose general managers have left, some are innovative drug companies, and some are traditional Chinese medicine companies, which shows that both traditional pharmaceutical companies and innovative drug companies are currently facing severe challenges
.
The industry believes that to a certain extent, the departure of some pharmaceutical executives implies that the transformation of enterprises is facing problems such as
insufficient growth momentum.
For example, in the field of traditional Chinese medicine, with the deepening of pharmaceutical reform and the promotion of the collection of proprietary Chinese medicines in Beijing, Shandong, Hubei and other places, the performance of traditional Chinese medicine enterprises is generally under pressure, and transformation is imminent, and the personnel changes of enterprises are also accelerating
in this context.
In recent years, pharmaceutical companies including Yunnan Baiyao and Tablet Zai Zhen are actively transforming and strengthening innovation and research and development, and the accompanying executive changes have also accelerated, such as the chairman of the board of directors
has been replaced twice in 2021.
In addition, in the context of accelerated transformation of innovative drug companies, executive talent changes are becoming more frequent
.
From the perspective of the flow of executives of local innovative pharmaceutical companies, many executives are flowing from multinational pharmaceutical companies to local innovative pharmaceutical companies, which reflects the strong
demand for high-level talents of local innovative pharmaceutical companies.
The industry believes that China's various conditions in pharmaceutical innovation have been gradually improved, whether it is talent, capital, policy or market demand, it shows that China's innovative research and development is entering the harvest period, which is also the reason for attracting multinational pharmaceutical talents to flow into the local market
.
However, many multinational pharmaceutical talents have not worked in local pharmaceutical companies for a long time, and even returned to their "old owners" of multinational pharmaceutical companies
.
This is mainly related to "water and soil", and may also require local pharmaceutical companies to pay more attention to talents, reduce the intervention of capital, and focus on the value of innovation itself
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.
